Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
Follicular dendritic cell sarcoma is a rare, malignant, non-lymphoid cell-derived tumor that originates from B-lymphoid follicles of nodal and extranodal sites. It has been reported in around 100 cases in the literature, mostly for the head and neck region. Surgery and radiotherapy were considered the mainstay of treatment for localized disease. As for the metastatic setting, classic lymphoma and sarcoma regimens were previously tested with dismal responses.


METHODS
In this report, we examined imatinib in combination with gemcitabine and cisplatin for treating a male patient with metastatic follicular dendritic sarcoma to the liver and lung.


RESULTS
The patient achieved complete pathological remission confirmed by positron emission tomography (PET) scan after 8 cycles.


CONCLUSIONS
Our case is the first to report a role for imatinib and to show complete pathological remission in this rare disease. An imatinibbased combination could serve as a good therapeutic option for such cases.
Azim
Hamdy A
HA
Clinical Oncology Department, Cairo University Hospital, Egypt.
Elsedewy
Ehab
E
Azim
Hatem A
HA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D020566:Dendritic Cells, Follicular / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000093542:Gemcitabine
D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D003841:Deoxycytidine; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D002945:Cisplatin; D000093542:Gemcitabine